Klaria Pharma Holding AB (KLAR) AI Stock Analysis

Klaria Pharma Holding AB

(Nasdaq OMX AB:KLAR)

Select Model

Rating:41Neutral

Price Target:SEK 0.52▼(-0.38% Downside)

Action:upgraded

Date:10/11/26

The score is driven primarily by very weak financial performance (persistent heavy losses, ongoing cash burn, and negative equity). Technicals are also unfavorable with the price below key moving averages and negative MACD, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend yield data.

Positive Factors

Buccal film platformKlaria has a defined technology platform rather than an undifferentiated drug-development approach. Applying buccal thin-film delivery across therapeutic areas could support multiple product programs and create reusable development expertise if candidates progress successfully.

Negative Factors

Minimal revenue and persistent lossesThe company has not yet demonstrated a sustainable commercial earnings base: TTM revenue is minimal while losses remain very large and margins are sharply negative. Persistent losses reduce internal funding capacity and leave future value dependent on successful product progress or external financing.

Klaria Pharma Holding AB (KLAR) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 132.58M
Dividend Yield: ―
Average Volume (3M): 910.79K
Price to Earnings (P/E): -3.2
Beta (1Y): 1.81
Revenue Growth: -99.01%
EPS Growth: 38.00%
Country: Sweden
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Klaria Pharma Holding AB Business Overview & Revenue Model

Company Description

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. W...

How the Company Makes Money

Klaria Pharma Holding AB’s primary path to monetization is typical of early-stage/specialty pharma development companies: progressing product candidates and its drug-delivery platform toward partnering and/or commercialization. Key expected revenue s...

Klaria Pharma Holding AB Financial Statement Overview

Summary

Financial strength is very weak: minimal TTM revenue (116k), large net loss (~38.7m) with sharply negative margins, negative operating cash flow (about -48.5m) and negative free cash flow, plus negative stockholders’ equity in TTM and 2025—raising financing and recapitalization risk despite currently lower debt.

Income Statement

14Very Negative

Balance Sheet

22Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	116.00K	9.00M	2.25M	8.45M	5.87M	6.11M
Gross Profit	2.84M	-2.23M	2.25M	8.45M	5.87M	-4.85M
EBITDA	-23.20M	-9.20M	-19.99M	-20.81M	-44.80M	-39.41M
Net Income	-38.73M	-38.90M	-47.75M	-35.78M	-63.77M	-53.53M
Balance Sheet
Total Assets	37.47M	40.77M	57.27M	72.95M	120.27M	118.31M
Cash, Cash Equivalents and Short-Term Investments	8.47M	342.00K	598.00K	1.25M	16.76M	25.49M
Total Debt	9.70M	0	23.07M	18.93M	17.09M	31.72M
Total Liabilities	71.08M	44.65M	53.96M	31.81M	44.19M	48.89M
Stockholders Equity	-33.62M	-3.88M	3.31M	41.13M	76.08M	69.41M
Cash Flow
Free Cash Flow	-13.48M	-35.04M	-11.94M	-3.37M	-49.77M	-24.80M
Operating Cash Flow	-48.51M	-35.04M	-11.94M	-9.06M	-49.73M	-24.80M
Investing Cash Flow	0	0	0	0	-42.00K	0
Financing Cash Flow	55.01M	34.78M	11.27M	-6.46M	41.06M	19.04M

Klaria Pharma Holding AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.52

Price Trends

50DMA0.63Negative

100DMA0.73Negative

200DMA0.81Negative

Market Momentum

MACD-0.03Negative

RSI45.06Neutral

STOCH45.47Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KLAR, the sentiment is Neutral. The current price of 0.52 is below the 20-day moving average (MA) of 0.53, below the 50-day MA of 0.63, and below the 200-day MA of 0.81, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 45.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:KLAR.

Klaria Pharma Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:KLAR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
SE:XBRANE	53Neutral	SEK 291.57M	-5.90	-11.52%	―	-38.80%	-120.18%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ISOFOL	49Neutral	SEK 383.95M	-5.99	-54.41%	―	―	32.79%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:IRLAB.A	46Neutral	SEK 310.81M	-3.21	-97.06%	―	4.74%	66.33%
SE:KLAR	41Neutral	SEK 132.58M	-3.24	289.25%	―	-99.01%	38.00%

* Healthcare Sector Average

Performance Comparison

SE:KLAR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:KLAR	Klaria Pharma Holding AB	0.54	0.02	4.05%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.51	238.45%
SE:XBRANE	Xbrane Biopharma AB	14.15	3.35	31.02%
SE:ISOFOL	Isofol Medical AB	1.20	0.51	74.89%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	2.09	-0.40	-15.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 11, 2026

Klaria Pharma Holding AB AI Stock Analysis